News

Regulatory news and analysis for GRAS teams.

Technical commentary on FDA-facing workflows, GRAS process development, and the regulatory systems shaping food ingredient review in the United States.

GRAS fundamentals

What Are the Parts of a GRAS Dossier?

Understand the seven core components that organize ingredient identity, manufacturing, exposure, safety evidence, literature, and the final GRAS conclusion.

Read article

Regulatory systems

Decision-tree systems are becoming central to FDA-facing GRAS strategy

Decision trees are not a substitute for scientific judgment, but they are increasingly useful for structuring how teams identify regulatory pathways, isolate unresolved questions, and decide whether a dossier is ready for external review.

In GRAS work, the most important early question is rarely whether a document can be drafted. The more consequential question is whether the dossier logic can withstand systematic review. Decision-tree systems help make that review explicit by forcing teams to test identity, manufacturing, exposure, specifications, and safety support against defined checkpoints.

For FDA-facing work, this matters because a no-questions outcome depends on the coherence of the record, not merely the presence of citations. A well-designed decision tree can expose where the submission basis is scientific-procedure GRAS rather than common-use GRAS, where intended conditions of use are too broad, where exposure assumptions are not yet defensible, and where a safety narrative has not connected the underlying data to the proposed use.

The best systems are not generic checklists. They are section-aware, evidence-sensitive, and traceable. They preserve the reasoning path that led to a readiness conclusion and make it easier for regulatory, scientific, and legal reviewers to identify the precise point at which additional support is required.

Decision trees convert implicit review judgment into explicit dossier gates.
They help distinguish missing information from unresolved regulatory risk.
They are most effective when paired with precedent retrieval and expert review.

FDA GRAS notice inventory

GRAS policy

GRAS self-certification in the United States: current status and practical implications

The U.S. GRAS framework continues to permit qualified expert determinations outside FDA premarket approval, but the policy environment is under active scrutiny. For sponsors, the practical standard is moving toward greater documentation, transparency, and review readiness.

Under the U.S. food safety framework, a substance may be excluded from the food additive approval requirement when its safety is generally recognized among qualified experts under the intended conditions of use. FDA's voluntary GRAS notification program gives companies a pathway to submit a notice and receive a response letter, including the familiar outcome that FDA has no questions regarding the notifier's GRAS conclusion.

That framework is distinct from mandatory premarket food additive approval. FDA has explained that a GRAS conclusion can be made by qualified experts outside government, while the agency's notification program provides a mechanism for review of the submitted basis. The result is a system that has historically allowed both notified GRAS conclusions and self-affirmed GRAS conclusions that are not submitted to FDA.

The current policy environment is changing. In March 2025, HHS directed FDA to explore potential rulemaking to revise the GRAS final rule and related guidance, specifically targeting the self-affirmed pathway. As of this writing, the core practical takeaway is not that every self-affirmed GRAS conclusion has disappeared, but that sponsors should expect increased pressure for stronger records, clearer expert rationale, and better readiness for regulatory scrutiny.

GRAS status remains tied to intended conditions of use, not ingredient identity alone.
FDA notification is voluntary, but a no-questions letter can create meaningful regulatory confidence.
Self-affirmed GRAS determinations should be documented as if they may later be reviewed.

FDA GRAS notification program